Skip to main navigation Skip to search Skip to main content

Cross-Sectional Characterization of Albumin Glycation State in Cerebrospinal Fluid and Plasma from Alzheimer's Disease Patients

  • M. Costa
  • , A. Mestre
  • , R. Horrillo
  • , A. M. Ortiz
  • , A. Pérez
  • , A. Ruiz
  • , M. Boada
  • , S. Grancha

Research output: Contribution to journalArticlepeer-review

Abstract

We determined albumin post-translational modifications (PTMs) by mass spectrometry (MS) in plasma and cerebrospinal fluid (CSF) from 31 Alzheimer's disease (AD) patients (with 27 samples of paired plasma-CSF from the same patients). Results were cross-sectionally compared with healthy controls. For percentage of relative intensity of glycated isoforms, plasma albumin was globally more glycated in AD patients than in healthy controls (P<0.01). MS results in plasma were confirmed by a quantitative enzymatic assay (Lucica GA-L) for albumin early-glycation detection. In CSF there were no global glycation differences detected by MS, although a different pattern of glycated isoforms was observed. Oxidized+glycated and cysteinylated+glycated isoforms were increased in both plasma and CSF of AD patients in comparison with healthy controls (P<0.001). Furthermore, AD patients showed higher glycation in plasma than in CSF (P<0.01). Our data support the role of glycation and oxidative stress in AD.

Original languageEnglish (US)
Pages (from-to)139-143
Number of pages5
JournalThe journal of prevention of Alzheimer's disease
Volume6
Issue number2
DOIs
StatePublished - 2019
Externally publishedYes

Keywords

  • Albumin
  • Alzheimer’s disease
  • cerebrospinal fluid
  • glycation status
  • plasma

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health

Fingerprint

Dive into the research topics of 'Cross-Sectional Characterization of Albumin Glycation State in Cerebrospinal Fluid and Plasma from Alzheimer's Disease Patients'. Together they form a unique fingerprint.

Cite this